3 “Strong Buy” Stocks from Wall Street – Week of 12/17

When a stock is rated as a “strong buy,” it typically means that analysts believe the stock has significant potential for growth and that the current price is undervalued. Analysts use a variety of methods to evaluate stocks, including financial analysis, market trends, and company performance. A “strong buy” rating is typically the highest rating an analyst will give to a stock.

Here are three “Strong Buy” stocks from Wall Street –

Akero Therapeutics, Inc. – SYM: AKRO
Recent Price: $23.09
Price Target: $45.78
Firms with Buy Rating: J.P. Morgan, Jefferies, UBS
Description: Akero Therapeutics, Inc., a clinical-stage company, engages in the development of transformational treatments for patients with serious metabolic diseases, including non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Its lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body.

===
WWIII Set to Trigger Dollar Collapse in December?

After correctly predicting the current inflation crisis and de-dollarization…

Teeka Tiwari believes that this war-related government event that’s scheduled for this month…

Will trigger the final collapse of the purchasing power of the dollars in your wallet, your checking account, and your retirement savings account.

Click here and learn the three steps you need to take to prepare.
===

BridgeBio Pharma, Inc. – SYM: BBIO
Recent Price: $39.37
Price Target: $50.13
Firms with Buy Rating: J.P. Morgan, Goldman Sachs, Citi
Description: BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

===
Unlocking the Power of the Nervous System Is a $100B Opportunity

Detecting nerve signals could help treat everything from high blood pressure to pain. Our revolutionary nerve-sensing technology has shown to be thousands of times more sensitive than what’s available today. Join us as we aim to revolutionize treatment for millions of people.

DOWNLOAD THE AUTONOMIX INVESTOR DECK TODAY
===

Everest Group, Ltd. – SYM: EG
Recent Price: $361.34
Price Target: $462.75
Firms with Buy Rating: Wells Fargo, Raymond James, Morgan Stanley
Description: Everest Group, Ltd., through its subsidiaries, provides reinsurance and insurance products in the United States, Bermuda, and internationally. The company operates through Reinsurance Operations and Insurance Operations segments. The Reinsurance Operations segment writes property and casualty reinsurance; and specialty lines of business through reinsurance brokers, as well as directly with ceding companies in the United States, Bermuda, Ireland, Canada, Singapore, Switzerland, and the United Kingdom. The Insurance Operations segment writes property and casualty insurance directly, as well as through brokers, surplus lines brokers, and general agents in the United States, Bermuda, Canada, Europe, South America, France, Germany, Spain, Canada, Chile, the United Kingdom, Ireland, and the Netherlands. The company also provides treaty and facultative reinsurance products; admitted and non-admitted insurance products; and property and casualty reinsurance and insurance coverages, including marine, aviation, surety, errors and omissions liability, directors’ and officers’ liability, medical malpractice, mortgage reinsurance, other specialty lines, accident and health, and workers’ compensation products. In addition, it offers commercial property and casualty insurance products through wholesale and retail brokers, surplus lines brokers, and program administrators. The company was formerly known as Everest Re Group, Ltd. and changed its name to Everest Group, Ltd. in July 2023. The company was founded in 1973 and is headquartered in Hamilton, Bermuda.